

# *Pathology – the missing link in global health care delivery*

## **Quentin Eichbaum**

MD, PhD, MPH, MFA, MMHC, JD, BSc(Med)(Hons), BA(Hons), FCAP, FASCP

Professor of Pathology, Microbiology and Immunology



Professor of Medical Education and Administration

Director, Transfusion Medicine (TVHS VA ) ((VUMC)

Director, Transfusion Medicine Fellowship Program

Director, Vanderbilt Pathology Program in Global Health





*“It is difficult to deliver effective and high quality care to patients without knowing their diagnosis.*

*Chris Murray & Lopez, Global Burden of Disease.*

# Pathology Practice in LMICs – a wide range of labs & health centers



# Diagnostics/Pathology - vital link in Health Delivery System

## GENERALLY APPRECIATED



1. **Diagnosis – right dx, for right patient, at right time**

## LESS APPRECIATED

1. **Disease staging & prognosis** - ongoing assessment to support clinical care
2. **Monitoring clinical response to treatment**
3. **Disease surveillance** eg disease registries
4. **Laboratory quality assurance within health care system**


# LMICs – Diagnostics needed not only for infectious/CDs but increasingly Non-Communicable Diseases (NCD)

-



Butler, Nature 2011

# Diagnosics Capacity in Africa - number of pathologists, technologists



Country	Population (No.)	No. of Persons per Pathologist	Pathologists	Histopathology Technicians	Cytopathology Technicians
Angola	24,906,000	2,096,000	13	23	7
Benin	10,567,000	NA	0	4	0
Botswana	2,156,000	359,333	6	3	8
Burkina Faso	18,184,000	2,273,000	8	4	0
Burundi	9,684,000	3,228,000	3	3*	0
Cameroon	21,636,000	3,606,000	6	2	3
Central African Republic	5,462,000	1,365,500	4	3	0
Chad	13,439,000	6,719,500	2	2	0
Cote d'Ivoire	24,926,000	1,661,733	15	8	1
Democratic Republic of Congo	74,081,000	4,938,733	15	21	4
Ethiopia	89,060,000	1,619,273	55	19	1
Gabon	2,337,000	779,000	3	8	0
Ghana	27,379,000	912,633	30	6+	4
Kenya	43,558,000	725,967	60	10+	4
Madagascar	22,747,000	NA			
Malawi	16,056,000	1,784,000	9	1	1
Mali	17,512,000	3,502,400	5	3	0
Mauritania	3,716,000	1,238,667	3	4	1
Mauritius	1,262,000	84,133	15	4	3
Mozambique	25,392,000	3,174,000	8	17†	6
Namibia	2,217,000	554,260	4	5	3
Niger	18,529,000	9,264,500	2	2	
Nigeria	182,336,000	1,072,565	170	1,400†	1
Republic of Congo	4,638,000	1,546,000	3		
Rwanda	11,180,000	2,236,000	5	10+	2
Senegal	13,950,000	1,992,857	7		
Sierra Leone	6,432,000	6,432,000	1	0	0
South Africa	54,425,000	224,897	242	69	94
South Sudan	12,165,000	6,082,500	2	0	0
Tanzania	48,126,000	2,187,545	22	20	20
Togo	6,967,000	2,322,333	3	2	0
Uganda	35,225,000	1,467,708	24	13	5
Zambia	15,254,000	2,542,333	6	4+	2
Zimbabwe	13,426,000	2,685,200	5	1	0



# Uniqueness of Pathology as a medical specialty?

Built on another underlying discipline –

**THE CLINICAL/ANATOMIC LABORATORIES**




# Interdependence of laboratory and clinical services

*“.. clinicians can lose confidence in laboratory services, and **resort to presumptive diagnoses** rather than laboratory information. In return, laboratory staff can become demotivated by the lack of faith in their profession.”*

*World Bank Group 2014: Laboratory professionals in Africa: the backbone of quality diagnostics*

## Box 1: A Vicious Cycle



# Effect of Inadequate Pathology Diagnostic Services in Low Resource Settings

Mis/under-diagnosis leads to inadequate treatment referral



Inadequate referral > inadequate follow-up



Treatment delays  
Poorer clinical outcomes  
Suboptimal/wasteful use of limited resources in LRS.



Inadequate reporting of disease rates, incidence, prevalence,  
mortality  
Limits ability to plan for medical care needs in LRS





**World Health  
Organization**

REGIONAL OFFICE FOR  
**Africa**

---

---

# **The Maputo Declaration**

**2008**

---

---



---

## **The Maputo Declaration on Strengthening of Laboratory Systems**

**Call** on national governments to support laboratory systems as a priority by developing a national laboratory policy within the national health development plan that will guide the implementation of a national strategic laboratory plan. Governments should establish a department of laboratory systems within the Ministry of Health.

**Call** on national governments with support of their donors and partners in resource-limited settings to develop national strategic laboratory plans that integrate laboratory support for the major diseases of public health importance including HIV, tuberculosis, and malaria.

**Call** on donors and implementing partners to ensure that in supporting laboratory strengthening that proper consideration is given to fostering national ownership.

**Call** on countries and all partners to urgently address the broader laboratory human resources agenda for laboratory strengthening including training, recruitment and retention of laboratory workers and their adequate financing.

**Call** on donors and development partners to **commit** to work collaboratively with each other and with coordination from the national governments to support strengthening of laboratory systems in order to create one unified, integrated national laboratory network. These laboratory strengthening efforts should seek to build public private partnerships.

**Call** on academic institutions and research funders to accelerate efforts to develop new diagnostic tools applicable to resourced-limited settings



Figure 1: Stakeholder governance structure



What is SLMTA?

Strengthening Laboratory Management Toward Accreditation

What is SLIPTA?

Stepwise Laboratory Quality Improvement Process Towards Accreditation

SLMTA	SLIPTA
A toolkit for training and mentoring	A framework for auditing and monitoring
Prepares and supports laboratory quality improvement	Checks and monitors the improvement process using the SLIPTA checklist
Develops work plans and executes improvement projects	Identifies gaps, non-conformities and provides recommendations for corrective actions
Implemented by laboratory personnel (laboratory managers)	Audits performed by ASLM-certified SLIPTA auditors
Graduates on SLMTA and prepares for inspection	Determines star level and provides Certificate of Recognition (1-5 star levels)

# Improving efficiency and effectiveness of Diagnostic Testing in LMICs?

1. Essential Diagnostics Lists (HICs > LMICs?)
2. Tiered laboratory testing

# 1 Time for a Model List of Essential Diagnostics


Lee F. Schroeder, M.D., Ph.D., Jeannette Guarner, M.D., Ali Elbireer, Ph.D., M.B.A., Philip E. Castle, Ph.D., M.P.H., and Timothy K. Amukele, M.D., Ph.D. N ENGL J MED 374:26 NEJM.ORG JUNE 30, 2016

Essential Medicines List (EML) of 300 medicines matched with lab tests essential for at least one of them – 147 tests sorted into 57 categories

- (1) diagnosing conditions for which medicine indicated
- (2) monitoring medication efficacy
- (3) monitoring medication toxicity.

Selected Laboratory Tests That Are Required for Use of Medicines on the WHO Model List of Essential Medicines (EML).		
Test	No. of Medicines on EML	EML Categories
Complete blood count	136	Affecting blood; anesthetics; antidotes; antiepileptics; antihepatitis; anti-infectives; antimigraine; antiparkinsonism; blood products; cardiovascular; dermatologic; diuretics; gastrointestinal; hormones; immunologics; ophthalmic; oxytocics; palliative; psychiatric; rheumatologic
Liver enzymes	104	Anesthetics; antidotes; antiepileptics; antihepatitis; anti-infectives; antimigraine; antiparkinsonism; cardiovascular; diuretics; gastrointestinal; hormones; oxytocics; palliative; psychiatric; rheumatologic; vitamins
Renal function	92	Anesthetics; anti-allergics; antidotes; antiepileptics; antihepatitis; anti-infectives; antimigraine; antiparkinsonism; blood products; cardiovascular; diagnostic agents; diuretics; ear, nose, and throat; gastrointestinal; hormones; immunologics; palliative; psychiatric; respiratory; rheumatologic
Microscopy	85	Anti-infectives; blood products; dermatologic; hormones
Urinalysis	64	Anesthetics; antidotes; antiepileptics; antihepatitis; anti-infectives; blood products; cardiovascular; electrolyte solutions; gastrointestinal; hormones; immunologics; oxytocics; psychiatric
Nucleic acid testing, microbiology	62	Antihepatitis; anti-infectives; hormones; immunologics; ophthalmic
Electrolytes	56	Anesthetics; anti-allergics; antidotes; anti-infectives; cardiovascular; diuretics; electrolyte solutions; ear, nose, and throat; gastrointestinal; hormones; ophthalmic; palliative; psychiatric; respiratory
Microbiologic culture (includes drug sensitivities)	51	Anti-infectives; dermatologic; immunologics; ophthalmic
Glucose	42	Affecting blood; anti-allergics; antidotes; anti-infectives; cardiovascular; electrolyte solutions; gastrointestinal; hormones; immunologics; neonatal; palliative; psychiatric
Antigen testing (microbiology)	42	Antihepatitis; anti-infectives; gastrointestinal; immunologics
Serology (microbiology)	41	Antihepatitis; anti-infectives; hormones; muscle relaxants; ophthalmic
Human chorionic gonadotropin	30	Affecting blood; antidotes; antihepatitis; anti-infectives; hormones; immunologics; psychiatric
Biochemical bacterial typing	27	Anti-infectives; immunologics; ophthalmic
Lipid panel	24	Anti-infectives; cardiovascular; hormones; psychiatric
Lymphocyte CD4	21	Anti-infectives; immunologics
Blood-gas testing	18	Affecting blood; anesthetics; antidotes; anti-infectives; electrolyte solutions; hormones; muscle relaxants; neonatal
Coagulation function	14	Affecting blood; antiepileptics; anti-infectives; blood products; hormones; immunologics; psychiatric
Glycated hemoglobin	11	Anti-infectives; cardiovascular; hormones; immunologics; neonatal; psychiatric
Calcium	10	Anti-allergics; antidotes; cardiovascular; diuretics; ear, nose, and throat; gastrointestinal; palliative; respiratory; vitamins

## 2. Tiered Approach to Pathology Testing



# Pathology Tiers 1 & 2 – Proposed Tests

(Adapted from Fleming et al, WHO, Cheesebrough, Kost, others)


Tier 1	Tier 2 (includes Tier 1 capabilities)
<p>1. <b>POCT and single user tests</b> -malaria, TB, HIV urinalysis, pregnancy tests, blood glucose</p> <p>2. <b>Slide microscopy</b> (eg malaria, wet preps, stool parasites);</p> <p>3. <b>Preparation of FNAC and tissue specimens to send to Tier 2</b></p>	<p><b><u>Routine and prognostic tests:</u></b></p> <p><b>Clinical biochemistry -</b> Electrolytes ; Hgb A1c, LFTs, renal, bone (T3?), lipid profiles,</p> <p><b>Hematology –</b> CBC, CD4, whole blood transfusion/blood type, coagulation, thalassemia</p> <p><b>Microbiology –</b> Cultures – blood (T1?), urine, cerebrospinal fluid, sputum Basic microbial antibiotic resistance testing; Serology testing for hepatitis A/B/C , common infections</p> <p><b>Anatomic Pathology –</b> FNAC, tissue biopsies, surgical excisions – processing of H&amp;E stain and interpretation; hospital autopsy</p>

# Tiered Pathology Test Approach –

Integrated network of labs working across tiers with clinicians

1. Testing appropriate to geographic and healthcare **CONTEXTS**
2. **LESS COSTLY** than attempting full menu testing everywhere
3. **EASIER TO MAINTAIN** fewer quality standards, less equipment
4. More **EFFECTIVE HEALTH DELIVERY**

# Is Point of Care Testing (POCT) the Solution – easy to **perform, interpret, communicate?**



*“...unplanned and uncoordinated growth of point of care testing, to the detriment of controlling health and improving outcomes.”*

# P.O.C.T – Effectiveness Criteria-

1. Test must **provide results for a specific clinical problem to guide clinical decisions in a time frame** for monitoring disease status or response to therapy, or to collect data for disease surveillance
2. Establish **performance criteria** prior to development of test
3. Test platforms must be **affordable, usable and stable** in locations of intended use
1. Meet **procurement requirements** for supply chain, maintenance, availability of quality control standards, durability, climate stability

## Box 11: A Virtuous Cycle



# Take Home Messages

- 1. Inaccurate diagnostics = waste and higher costs downstream**
  - Low resource settings cannot afford such waste
- 2. Pathology is an integral part of health system that links the right diagnosis, right person, right time with effective treatment outcomes**
- 1. Sustainability of diagnostic services** depends on (1) Effective laboratory systems (2) education, training and accreditation systems; (2) quality standards; (3) buy-in of MOHs; (4) lab information systems; (5) reimbursement

THANK YOU

[quentin.eichbaum@vanderbilt.edu](mailto:quentin.eichbaum@vanderbilt.edu)

TEL: 615-936-5124